Pulmonary manifestations of bioterrorism

Current Infectious Disease Reports

Volumn 3, Issue 3, 2001, Pages 249-257

  Heddurshetti, Renuka ^a   Pumpradit, Wadchara ^a   Lutwick, Larry I ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Avian Influenza; Biological Weapon; Plague; Protective Antigen; Yersinia Pestis

Indexed keywords

EID: 0000545853     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-001-0027-2     Document Type: Article

References (53)

1. Christopher GW, Cieslak TJ, Pavlin JA, et al.: Biological warfare. A historical perspective. JAMA 1997, 278:412–417.
2. Franz DR, Jahrling PB, Friedlander AM, et al.: Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997, 278:399–411.
3. Cieslak TJ, Eitzen EM Jr: Clinical and epidemiologic principles of anthrax. Emerg Infect Dis 1999, 5:552–555.
4. WHO groups of consultants: Health Aspects of Chemical and Biological Weapons. Geneva: World Health Organization; 1970:97–99.
5. Simon JD: Biological terrorism: preparing to meet the threat. JAMA 1997, 278:428–430.
6. Cole LA: The specter of biological weapons. Sci Am 1996, 275:60–65.
7. Inglesby TV, Henderson DA, Barlett JG, et al.: Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 1999, 281:1735–1745.One of the three (as of this writing) summary statements from the Working Group on Civilian Biodefense. These excellent and up-to-date documents will help clinicians recognize and understand each condition discussed.
8. Dixon TC, Meselson M, Guillemin J, et al.: Anthrax. N Engl J Med 1999, 341:815–826.A well-written summary on anthrax that will complement the biowarfare literature.
9. Friedlander A, Welkos SL, Pitt ML, et al.: Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993, 167:1239–1242.
10. Meselson M, Guillemin J, Hugh-Jones M, et al.: The Sverdlovsk anthrax outbreak of 1979. Science 1994, 266:1202–1208.
11. Henderson DW, Peacock S, Belton FC: Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hygiene 1954, 54:28–36.
12. Aramova FA, Grinberg LM, Yampolskaya O: Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak in 1979. Proc Natl Acad Sci U S A 1993, 90:2291–2294.
13. Vessal K, Yeganehdoust J, Duttz W, et al.: Radiologic changes in inhalation anthrax. Clin Radiol 1975, 26:471–474.
14. Lew D: Bacillus anthracis (anthrax). In Principles and Practices of Infectious Disease. Edited by Mandell GL, Bennett JE, Dolin R. New York: Churchill Livingstone; 2000:2215–2220.
15. Alizad A, Ayoub EM, Makki N: Intestinal anthrax in a two year old child. Pediatr Infect Dis J 1995, 14:394- 395.
16. Pile JC, Malone JD, Eitzen EM, et al.: Anthrax as a potential biological warfare agent. Arch Intern Med 1998, 158:429–434.
17. Stern J: The prospect of domestic bioterrorism. Emerg Infect Dis 1999, 5:517–522.
18. Cieslak TJ, Christopher GW, Kortepeter MG, et al.: Immunization against potential biological warfare agents. Clin Infect Dis 1999, 30:843–850.
19. Brachman PS, Gold H, Plotkin SA, et al.: Field evaluation of a human anthrax vaccine. Am J Pub Health 1962, 52:632–645.
20. Russell PK: Vaccine in civilian defense against bioterrorism. Emerg Infect Dis 1999, 5:531–533.
21. Nass M: Anthrax vaccine: a model of a response to the biologic warfare threat. Infect Dis Clin North Am 1999, 13:187–208.Well-organized exposé on anthrax vaccine and its implications for the military-biological complex.
22. Ivins B, Fellows P, Pitt L, et al.: Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Vaccine 1995, 13:1779–1784.
23. Bioterrorism alleging use of anthrax and interim guidelines for management-United States, 1998. MMWR Morbid Mortal Wkly Rep 1999, 48:69–74.
24. Perry RD, Fetherston JD: Yersinia pestis: etiologic agent of plague. Clin Microbiol Rev 1997, 10:35–66.
25. Welty TK, Grabman J, Kompare E: Nineteen cases of plague in Arizona: a spectrum including ecthyma gangrenosum due to plague and plague in pregnancy. West J Med 1985, 142:641–646.
26. Hull HF, Montes JM, Mann JM: Septicemic plague in New Mexico. J Infect Dis 1987, 155:113–118.
27. Crook LD, Tempest B: Plague: a clinical review of 27 cases. Arch Intern Med 1992, 152:1253–1256.
28. Speck RS, Wolochow H: Studies on the experimental epidemiology of respiratory infections, VIII: Experimental pneumonic plague in Macacus rhesus. J Infect Dis 1957, 100:58–68.
29. Wu L-T: A Treatise on Pneumonic Plague. Geneva, Switzerland: League of Nations Health Organization; 1926.
30. Poland JD, Dennis DT: Plague. In Bacterial Infections of Humans:Epidemiology and Control. Edited by Evans AS, Brachman PS.New York: Plenum Medical Book; 1998:545–558.
31. Dennis D, Meier F: Plague. In Pathology of Emerging Infections. Edited by Horsburgh CR, Nelson AM. Washington, DC: ASM Press; 1997:21–47.
32. Brubaker RR: Factors promoting acute and chronic diseases caused by Yersiniae. Clin Microbiol Rev 1991;4:309–324.
33. Cavanaugh DC, Cadigan FC, Williams JE, et al.: Plague. In General Medicine and Infectious Diseases. Edited by Ognibene AJ, Barrett ON. Washington, DC: Office of The Surgeon General and Center of Military History; 1982.
34. Werner SB, Weidmer CE, Nelson BC, et al.: Primary plague pneumonia contracted from a domestic cat in South Lake Tahoe, California. JAMA 1984, 251:929–931.
35. Legters LJ, Cottingham AJ Jr, Hunter DH: Clinical and epidemiologic notes on a defined outbreak of plague in Vietnam. Am J Trop Med Hygiene 1970, 19:639–652.
36. Cleri DJ, Vernaleo JR, Lombardi LJ, et al.: Plague pneumonia disease caused by Yersinia pestis. Sem Respir Infect 1997, 12:12–23.
37. Institute of Medicine National Research Council: Detection and measurement of biological agents. In Chemical and Biological Terrorism: Research and Development to Improve Civilian Medical Response. Washington, DC: National Academy Press; 1999:95.
38. Inglesby TV, Dennis DT, Henderson DA, et al.: Plague as a biologic weapon: medical and public health management. JAMA 2000, 283:2281–2290. This complementary article to Inglesby et al. [7••] covers plague quite well.
39. McGovern TW, Friedlander A: Plague. In Medical Aspects of Chemical and Biological Warfare. Edited by Sidell FR, Takafuji ET, Franz DR. Falls Church, VA: Office of the Surgeon General, United States Army; 1997:479–502.
40. Russell P, Eley SM, Bell DL, et al.: Doxycycline or ciprofloxacin prophylaxis and therapy against experimental Yersinia pestis infection in mice. J Antimicrob Chemother 1996, 37:769–774.
41. Ehrenkranz NF, Meyer KF: Studies on immunization against plague, VIII: Study of three immunizing preparations in protecting primates against pneumonic plague. J Infect Dis 1955, 96:138–144.
42. Meyer KF, Cavanaugh DC, Bartelloni PJ, et al.: Plague immunization, I: Past and present trends. J Infect Dis 1974, 129(Suppl):S13-S18.
43. Titball RW, Eley S, Williamson ED, et al.: Plague. In Vaccines.Edited by Plotkin S, Mortimer EA. Philadelphia: WB Saunders;1999:734–742.
44. Heath DG, Anderson GW, Mauro JM, et al.: Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 1998, 16:1131- 1137.A good illustrative article on the application of new vaccine technologies.
45. Williams P, Wallace D: Unit 731: Japan’s Secret Biological Warfare in World War II. New York: Free Press; 1989.
46. Harris S: Japanese biological warfare research on humans: a case study of microbiology and ethics. Ann N Y Acad Sci 1992, 555:21–52.
47. Shortridge KF, Gao P, Guan Y, et al.: Interspecies transmission of influenza viruses: H5N1 virus and a Hong Kong SAR perspective. Vet Microbiol 2000, 74:141–147.
48. Cauthen AN, Swayne DE, Schultz-Cherry S, et al.: Continued circulation in China of highly pathogenic avian influenza viruses encoding the hemagglutinin gene associated with the 1997 H5N1 outbreak in poultry and humans. J Virol 2000, 74:6592–6599.
49. Mounts AW, Kwong H, Izurieta HS, et al.: Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997. J Infect Dis 1999, 180:505–508.
50. Buxton Bridges C, Katz JM, Seto WH, et al.: Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong. J Infect Dis 2000, 181:344–348.
51. Alibek KW: Biohazard: The Chilling True Story of the Largest Covert Biological Weapons Program in the World. New York: Random House; 1999.If you want to miss a few nights’ sleep, read this book on the biowarfare industry in the former Soviet Union.
52. Preston R: The Cobra Event. New York: Random House; 1997.
53. Marr JS, Baldwin J: The Eleventh Plague. New York: Harper Trade; 1998.